INTEGRATED QSAR, MOLECULAR DOCKING AND MOLECULAR DYNAMICS APPROACHES IN MODERN DRUG DESIGN
Keywords:
quantitative structure-activity relationship; QSAR; molecular docking; molecular dynamics; computer-aided drug design; virtual screening; ADMET; lead optimization.Abstract
Modern computer-aided drug design increasingly depends on the integration of ligand-based and structure-based methods rather than on the isolated use of a single computational technique. This article presents a structured methodological review of quantitative structure-activity relationship (QSAR) modeling, molecular docking, and molecular dynamics (MD) simulation as complementary components of a contemporary drug-design pipeline. The objective was to analyze how these approaches can be combined to improve hit prioritization, interpret structure-activity relationships, assess binding-mode plausibility, and evaluate the dynamic stability of ligand-target complexes. A focused literature synthesis was performed using fifteen internationally recognized methodological and application-oriented publications covering QSAR best practices, docking algorithms, MD simulation, free-energy estimation, ADMET prediction, and recent integrated case studies. The analysis shows that QSAR is most efficient for rapid activity prediction and chemical-space prioritization, docking provides structural hypotheses for ligand recognition, and MD supplies time-dependent information on conformational adaptation, interaction persistence, solvation, and complex stability. Their sequential and iterative integration reduces method-specific uncertainty and creates a more defensible basis for selecting compounds for synthesis and biological testing. However, predictive value depends strongly on data curation, external validation, applicability-domain assessment, receptor preparation, protonation-state control, force-field quality, simulation convergence, and experimental confirmation. The integrated strategy is therefore best regarded as a decision-support framework rather than a replacement for experimental pharmacology. The review proposes a practical workflow suitable for medicinal chemistry projects and emphasizes reproducibility, transparent validation, and prospective testing as key conditions for scientifically reliable use.
References
1. Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., et al. (2014). QSAR modeling: where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977-5010. https://doi.org/10.1021/jm4004285
2. Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024). Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nature Reviews Drug Discovery, 23(2), 141-155. https://doi.org/10.1038/s41573-023-00832-0
3. Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455-461. https://doi.org/10.1002/jcc.21334
4. Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. Journal of Chemical Information and Modeling, 61(8), 3891-3898. https://doi.org/10.1021/acs.jcim.1c00203
5. Ferreira, L. G., dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. Molecules, 20(7), 13384-13421. https://doi.org/10.3390/molecules200713384
6. Pagadala, N. S., Syed, K., & Tuszynski, J. (2017). Software for molecular docking: a review. Biophysical Reviews, 9, 91-102. https://doi.org/10.1007/s12551-016-0247-1
7. Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. Neuron, 99(6), 1129-1143. https://doi.org/10.1016/j.neuron.2018.08.011
8. Durrant, J. D., & McCammon, J. A. (2011). Molecular dynamics simulations and drug discovery. BMC Biology, 9, 71. https://doi.org/10.1186/1741-7007-9-71
9. Abraham, M. J., Murtola, T., Schulz, R., Pall, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19-25. https://doi.org/10.1016/j.softx.2015.06.001
10. Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449-461. https://doi.org/10.1517/17460441.2015.1032936
11. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
12. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104
13. Habib, I., Chohan, T. A., Chohan, T. A., Batool, F., Khurshid, U., Khursheed, A., et al. (2024). Integrated computational approaches for designing potent pyrimidine-based CDK9 inhibitors: 3D-QSAR, docking, and molecular dynamics simulations. Computational Biology and Chemistry, 108, 108003. https://doi.org/10.1016/j.compbiolchem.2023.108003
14. Abchir, O., Khedraoui, M., Nour, H., Yamari, I., Errougui, A., Samadi, A., & Chtita, S. (2024). Integrative approach for designing novel triazole derivatives as alpha-glucosidase inhibitors: QSAR, molecular docking, ADMET, and molecular dynamics investigations. Pharmaceuticals, 17(2), 261. https://doi.org/10.3390/ph17020261
15. Tong, J.-B., Xiao, X.-C., Luo, D., Xu, H.-Y., Xing, Y.-C., Gao, P., & Liu, Y. (2024). Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations. Molecular Diversity, 28(2), 671-692. https://doi.org/10.1007/s11030-023-10611-z
